Navigation Links
HealthEconomics.Com’s Pharma Pricing and Reimbursement Stories in This Week’s Newsletter
Date:4/1/2013

Ponte Vedra Beach, Florida (PRWEB) April 01, 2013

The top read story this week on HealthEconomics.Com was from a Healthy Criticism Blog posting by Nick Emptage, exploring why price transparency in pharmaceuticals and healthcare won’t reduce healthcare spending. Economist Emptage reflected on the business model of San Francisco-based Castlight Health, a company which contracts with employers to make the costs of health services transparent to employees. The idea is that employees will then lean toward lower-cost providers. Nick's blog points out the flaws of this idea as it relates to the health care market.

Another story of interest relates to comments by Jon Sussex, a member of the United Kingdom-based Office of Health Economics (OHE) Commission on Competition in the National Health Service (NHS). Sussex reflects on the revised draft of regulations to govern competition among providers of health care funded by the NHS in England; the first draft was replaced due to wide criticism. The article includes comments relating to the required use of competition by NHS in obtaining health care services for their populations unless there are good reasons not to do so.

The third most popular story on HealthEconomics.Com explored whether US taxpayers enjoy lower drug prices if federal money backed development. This question was based on actions by Senator Ron Wyden (Oregon-D), who has delved into this issue to explore the return-on-investment to the public based on tax dollar use for drug development. Should some of that return come in the form of lower prices on drugs developed with federal support? Original article sourced from FiercePharma.

About HealthEconomics.Com (http://www.healtheconomics.com):
A pioneer in the field, HealthEconomics.Com is the global authority in healthcare value and pharma market access. Each day, HealthEconomics.Com compiles the latest news, policy updates, resources, conferences, and jobs for BioPharma’s professionals involved in health economics, outcomes research, market access, and pricing. A trusted resource, HealthEconomics.Com’s comprehensive content is carefully selected by a discerning health economist editor, making it the most visited website for healthcare value and market access in the industry, with visitors encompassing all corners of the globe.

News Media interested in receiving the most current information on healthcare value and market access may obtain a free subscription to HealthEconomics.Com by visiting the site or by subscribing to the HealthEconomics.Com Newsletter.

Read the full story at http://www.prweb.com/releases/2013/4/prweb10586528.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. WuXi PharmaTech Announces Third-Quarter 2011 Results
3. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
4. Pharmasset Reports Fiscal Year End 2011 Financial Results
5. Internal and External Communications Excellence for the Pharmaceutical Industry: Increasing Organizational Effectiveness
6. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
7. PRA Expert to Present at Pharmacovigilance Conference
8. Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain
9. InnoPharma Completes $15 Million Series A Financing
10. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
11. ViroPharma to Participate in Two December Healthcare Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/11/2017)... ... January 11, 2017 , ... ... Research show early promise of the investigational anti-cancer agent tucatinib (formerly ONT-380) against ... previous treatment regimens. Twenty-seven percent of these heavily pretreated patients saw clinical benefit ...
(Date:1/11/2017)... , ... January 11, 2017 , ... ... year and costing healthcare systems more than $23.7 billion, healthcare systems are ... , Among the most common sepsis-causing pathogens are bacteria and the yeast ...
(Date:1/11/2017)... ... 11, 2017 , ... Symbios Technologies, Inc., a ... Science Foundation (NSF) has awarded Symbios a Small Business Innovation Research (SBIR) ... the Symbios Tubular Plasma Reactor™ (TPR™) by scaling the system for first customer ...
(Date:1/11/2017)... 11, 2017  GenVec, Inc. (NASDAQ: ... today that its chief scientific officer, Douglas ...  "AdenoVerse™ platform for translational development of innovative gene ... the upcoming Phacilitate Cell & Gene Therapy World ... Florida.  Dr. Brough,s presentation will highlight the utility ...
Breaking Biology Technology:
(Date:1/12/2017)...  Trovagene, Inc. (NASDAQ: TROV ), a ... that it has signed agreements with seven strategic partners ... Middle East for commercialization of the ... wave of international distribution agreements for Trovagene,s CLIA based ... The initial partners will introduce Trovagene,s liquid biopsy ...
(Date:1/11/2017)... -- Michael Johnson, co-founder of Visikol Inc. a company originally funded with ... to the elite "Forbes 30 Under 30" list in the Science ... 20 fields nationwide to be recognized as a leader in business ... ... a PhD candidate at Rutgers University. Visikol ...
(Date:1/4/2017)... thousands of attendees at this year,s International Consumer Electronics Show (CES), ... devices and services, will be featuring its new line of ULTRA CONNECT ... special CES Exhibit Suite , the new upper arm and wrist smart ... product platform.  Continue Reading ... ...
Breaking Biology News(10 mins):